The global pandemic promised a windfall for forward-thinking companies making products to help combat the spread of the coronavirus. Count the Stevanto Group, one of
Author: TNN Bureau
FDA waves through a third Sarepta DMD drug, once again based on questionable biomarker data
Sarepta Therapeutics has pushed its third Duchenne muscular dystrophy drug across the FDA finish line with controversial biomarker data—and this time without the regulatory drama.
Lilly scores $210M supply deal for newly authorized coronavirus antibody cocktail
As U.S. officials look to ramp up COVID-19 vaccinations heading into March, they’re not overlooking another pandemic-fighting tool. Eli Lilly on Friday scored a government
Novo Nordisk re-engages comedian Billy Gardell for branded Ozempic campaign
Actor and comedian Billy Gardell is definitely in the zone. The Type 2 diabetes health zone, that is. And he’s taking his good health to
Rocket Pharma spurs more buildings and landmarks to light up for Rare Disease Day
How does an orphan drug pharma company with offices in the Empire State Building amplify rare disease awareness? Ask Rocket Pharmaceuticals. The rare disease specialist
Fierce Pharma Asia—Daiichi Sankyo’s new R&D head; Clover’s $230M raise; Insilico’s AI breakthrough
Amid a big cancer push, Daiichi Sankyo lured Kite Pharma exec Ken Takeshita to lead its R&D work. China’s Clover Biopharmaceuticals secured $230 million in
Wayra, GE Healthcare launch accelerator programme for digital health start-ups
Wayra and GE Healthcare have launched an accelerator programme across the Europe, the Middle East and Africa (EMEA) region to support digital health start-ups to
ICON to acquire PRA Health Sciences in $12bn deal
Dublin-based clinical trials group ICON is set to acquire rival contract research organisation (CRO) PRA Health Sciences in a deal worth approximately $12bn. The deal
GSK’s COVID-19 antibody shows potential in older patients
GlaxoSmithKline (GSK) has reported Phase II results for its investigational monoclonal antibody otilimab in hospitalised COVID-19 patients – and the data is mixed. The primary
NICE recommends routine funding for Novartis’ Kisqali
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients. NICE’s draft